Thalidomide in solid malignancies

被引:24
作者
Eisen, T [1 ]
机构
[1] Royal Marsden Hosp, Sutton, Surrey, England
关键词
D O I
10.1200/JCO.2002.20.11.2607
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
引用
收藏
页码:2607 / 2609
页数:3
相关论文
共 24 条
[1]
Advances in disease biology: Therapeutic implications [J].
Anderson, KC .
SEMINARS IN HEMATOLOGY, 2001, 38 (02) :6-10
[2]
Brock CS, 1998, CANCER RES, V58, P4363
[3]
EFFECT OF THALIDOMIDE ON TUMOR-NECROSIS-FACTOR PRODUCTION AND ANTITUMOR-ACTIVITY INDUCED BY 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID [J].
CHING, LM ;
XU, ZF ;
GUMMER, BH ;
PALMER, BD ;
JOSEPH, WR ;
BAGULEY, BC .
BRITISH JOURNAL OF CANCER, 1995, 72 (02) :339-343
[4]
CRAWFORD CL, 1994, ADVERSE DRUG REACT T, V13, P177
[5]
THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].
DAMATO, RJ ;
LOUGHNAN, MS ;
FLYNN, E ;
FOLKMAN, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085
[6]
Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer [J].
Eisen, T ;
Boshoff, C ;
Mak, I ;
Sapunar, F ;
Vaughan, MM ;
Pyle, L ;
Johnston, SRD ;
Ahern, R ;
Smith, IE ;
Gore, ME .
BRITISH JOURNAL OF CANCER, 2000, 82 (04) :812-817
[7]
A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer [J].
Figg, WD ;
Arlen, P ;
Gulley, J ;
Fernandez, P ;
Noone, M ;
Fedenko, K ;
Hamilton, M ;
Parker, C ;
Kruger, EA ;
Pluda, J ;
Dahut, WL .
SEMINARS IN ONCOLOGY, 2001, 28 (04) :62-66
[8]
Fujita J, 2001, CLIN CANCER RES, V7, P3349
[9]
Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade [J].
Geitz, H ;
Handt, S ;
Zwingenberger, K .
IMMUNOPHARMACOLOGY, 1996, 31 (2-3) :213-221
[10]
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8+ subset [J].
Haslett, PAJ ;
Corral, LG ;
Albert, M ;
Kaplan, G .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (11) :1885-1892